Enhancing Pediatric Pain Management in Portuguese Emergency Departments: Progress and Challenges (2007-2018)

By João L. Carapinha

April 29, 2025

Pain assessment in Portuguese PEDs has seen substantial progress from 2007 to 2018. The adoption of local protocols and pain scales increased from 52% to 93%, based on a recently published study. However, pediatric pain management remains inadequate for mild to moderate pain, with only 22% of facilities consistently administering analgesia. Treatment for severe pain and opioid usage appears sufficient. Procedural sedation and analgesia have increased but are not universally practiced. Alarmingly, 88% of staff members recognize the need for enhanced training.

Advancements in Pain Assessment Practices

The implementation of pain assessment protocols and pain scales has increased dramatically:

  • Local pain management protocols rose from 52% in 2007 to 93% in 2018.
  • Pain scale usage reached 100% by 2018, showing a comprehensive approach.
  • By 2018, nurses became the primary pain assessors in all hospitals.

This improvement reflects the application of national guidelines after Portugal’s National Plan Against Pain (2001) and pediatric-specific guidelines.

Ongoing Challenges in Effective Pain Treatment

Despite assessment advancements, pain management still faces obstacles. More hospitals treat mild to moderate pain at least 50% of the time (91% in 2018 vs. 57% in 2007). Yet only 22% always provide analgesia, down from 43% in 2007. Analgesia for procedures remains underused: i) venipuncture analgesia is rarely given (83% never used it in 2018), ii) lumbar puncture analgesia saw no improvement, iii) fracture reduction and wound suture pain management improved. Use increased from 52% to 83%, but ethical concerns persist. Forced immobilization was reported in 26% of hospitals.

Importance of Addressing Pediatric Pain

Pain affects over 60% of PED admissions, making it critical in emergency care. Despite global awareness, pediatric pain management remains inadequate. Untreated pain can cause immediate anxiety and delayed care, plus long-term emotional harm and chronic pain risks. Since Portugal’s National Plan Against Pain (2001) and pediatric guidelines (2010), policy efforts have improved. However, local implementation varies.

The WHO states pain relief is a fundamental right and that inadequate management is substandard care. WHO guidelines recommend multimodal pediatric pain management, blending pharmacological and non-pharmacological methods.

Implications for Healthcare Quality and Economics

Cost Implications of Inadequate Pain Management

Poor pain management may lead to longer emergency stays, more return visits, extra resources for complications, higher long-term costs.

Necessity for Training and Resource Allocation

The study shows a demand for training (88% of staff seek more). Effective programs require staff education, protocol development, quality monitoring, and medication availability.

Future Research Directions

To address gaps, healthcare systems should:

  1. Standardize Protocols: Universal pain assessment and triage protocols.
  2. Invest in Education: Targeted training on opioid fears and symptom masking.
  3. Promote Quality Improvements: Regular audits and feedback.
  4. Allocate Resources Wisely: Ensure analgesic access in all PEDs.
  5. Encourage Research: Study cost-effectiveness and long-term outcomes.

While progress has been made in Portuguese PEDs, more work is needed to improve pain management. For details, see the original study here.

Reference url

Recent Posts

Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditional Recommendations

By João L. Carapinha

August 20, 2025

The National Institute for Health and Care Excellence (NICE) has issued consultative draft guidance recommending six digital cardiac rehabilitation technologies for adults with cardiovascular disease (CVD). These technologies are conditionally recommended for use in the NHS during a three-year ev...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit

By João L. Carapinha

August 19, 2025

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. The review...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rare Disease Therapies
Health technology assessment (HTA) plays a crucial role in determining whether new therapies are reimbursed within healthcare systems. At the July 18, 2025 meeting of the Adviescommissie Pakket (ACP), two high-profile orphan drugs—omaveloxolone (Skyclarys®) for Friedreich’s ataxia and exagamgloge...